Drug Profile
YM 758
Alternative Names: IFI-930A; YM 758 monophosphate; YM758Latest Information Update: 09 Sep 2015
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Cardeus Pharmaceuticals
- Class Antiarrhythmics; Ischaemic heart disorder therapies
- Mechanism of Action Cyclic nucleotide-gated cation channel antagonists; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Angina pectoris; Atrial fibrillation
Most Recent Events
- 31 Mar 2011 Phase-II clinical trials in Angina pectoris in Europe (PO)
- 31 Mar 2011 Phase-II clinical trials in Atrial fibrillation in USA (PO)
- 27 Dec 2007 Discontinued - Phase-II for Atrial fibrillation in USA (PO)